louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06387563: Effects of Abdominal Muscle Activation Training, Using Pressure Biofeedback in Comparison With Surface Electromyography
Official title: Effects of Abdominal Muscle Activation Training, Using Pressure Biofeedback in Comparison With Surface Electromyography
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Low Back Pain
Lead sponsor: Foundation University Islamabad
Sponsor class: OTHER
First posted: 2024-04-29
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 44
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomized control trial
Primary purpose: TREATMENT

Brief summary: This study is a randomized control trial and the purpose of this study to determine the effects of abdominal muscle activation training on non-specific low back pain; using pressure biofeedback in comparison with surface electromyography biofeedback: a randomized control trial.

Detailed description: The purpose of this study is to determine the effects of abdominal muscle activation training, using pressure biofeedback in comparison with surface electromyography biofeedback, in management of non-specific low back pain: a randomized control trial.

Pain and disability are the primary outcomes which will be determined using:

1. Numeric pain rating scale (NPRS)
2. Oswestry disability index (ODI) Data will be taken before and after the intervention protocol for each participant.

Data collection procedure: Participants of interest would be approached and explained about the research. Informed written consent will be taken. Pre and post intervention scores will be recorded.

Eligibility criteria: Inclusion Criteria:

* Age (adults 19 - 44 years)
* Non-specific LBP with NPRS \> 3
* Negative SLR test in prone and supine
* Painless extremity movement and activity
* Manual muscle testing of abdominal muscles between grade 2 - 4
* Sedentary individuals (no exercise plan followed in last 3 months)

Exclusion Criteria:

* History of any spinal surgery
* Degenerative disc disorder, facet joint syndrome, spinal stenosis, myelopathy, lumbar syringomyelia
* Sensory disturbances due to neurological causes, lumbar radiculopathy, fibromyalgia, myofascial pain syndrome
* Sacroiliac joint dysfunction
* Pregnancy
* Medical conditions; Hypertension, Diabetes mellites
* Work disability greater than 6 months
* Not able to attend regular therapy appointments

Primary outcomes:
measure: Pain Intensity
timeFrame: 4 weeks
measure: Level of Disability
timeFrame: 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Rawalpindi
country: Pakistan
facility: Foundation University College of Physical Therapy
state: Punjab
Study officials:
References:
Clinical trial NCT03108963: L-carnitine and Metformin in Obese PCOS Women.
Official title: L-carnitine Plus Metformin in Clomiphene-resistant Obese PCOS Women, Reproductive and Metabolic Effects: a Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: PCOS
Lead sponsor: Zagazig University
Sponsor class: OTHER_GOV
First posted: 2017-04-11
Enrollment: 280
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: L-carnitine and plus metformin in clomiphene-resistant obese PCOS women, reproductive and metabolic effect: a randomized clinical trial

Detailed description: the trial aims to compare L-carnitine and plus metformin in clomiphene-resistant obese PCOS women with placebo to state the reproductive and metabolic effects in form of pregnancy and insulin resistance parameters and lipid metabolism.

Eligibility criteria: Inclusion Criteria:

* pco
* obese
* ifertile

Exclusion Criteria:

* no medical disorders
* no hormonal treatment in the previous 3 months

Primary outcomes:
measure: pregnancy rate
timeFrame: 3 momths
Secondary outcomes:
measure: ovulation rate
timeFrame: 3 momths
measure: abortion rate
timeFrame: 3 momths
measure: insulin resistance
timeFrame: 3 momths
measure: lipid metabolism
timeFrame: 3 momths
Other outcomes:
Locations:
city: Zagazig
country: Egypt
facility: Zagazig University
Study officials:
affiliation: FACULTY OF MEDICINE ,ZAGAZIG UNIVERSITY
name: ibrahim A el sharkwy, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02231463: Influence of Two Different PEEP Niveaus and a Trendelenburg Positioning Manoeuvre on Subclavian Vein Diameter
Official title: Influence of Two Different PEEP Niveaus and a Trendelenburg Positioning Manoeuvre on Subclavian Vein Diameter as a Surrogate Parameter in Punctures of Central Veins
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Insufficiency; Cardiac, Complicating Surgery
Keywords: ultrasound
Lead sponsor: Universitätsklinikum Köln
Sponsor class: OTHER
First posted: 2014-09-04
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients undergoing a operative procedure which requires a central venous catheter

Brief summary: In 50 Patients who are undergoing a planned surgical procedure which require a central venous catheter the diameter of the subclavian vein is measured by ultrasound under 6 different conditions.

Detailed description: In 50 Patients who are undergoing a planned surgical procedure which require a central venous catheter the diameter of the subclavian vein is measured by ultrasound under 6 different conditions. The conditions are

1. neutral positioning, PEEP 0 cm H2O,
2. neutral positioning, PEEP 5cm H2O,
3. neutral positioning, PEEP 10cm H2O,
4. Trendelenburg positioning -20°, PEEP 0 cmH2O,
5. Trendelenburg positioning -20°, PEEP 5 cmH2O,
6. Trendelenburg positioning -20°, PEEP 10 cmH2O After these measurements a central venous catheter is used to measure the central venous pressure.

Eligibility criteria: Inclusion Criteria:

* Age \>18 years
* cardiosurgery or neurosurgery
* written informed consent
* ECG: inus rhythm

Exclusion Criteria:

* peacemaker
* kontraindications for PEEP
* pulmonary disease
* hemodynamically instable patients
* pregnancy
* pulmonal Hypertension
* ejection fraction \< 35%
* severe valvular disease
* tricuspid insufficiency

Primary outcomes:
measure: Diameter of vein
timeFrame: only 1 day (the day of the measurement); no follow-up is required
Secondary outcomes:
Other outcomes:
Locations:
city: Cologne
country: Germany
facility: UK Köln
state: NRW
Study officials:
affiliation: UK Köln
name: Jochen Hinkelbein, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05760963: Which Approach to Favor for Ultrasound-guided Lumbar Plexus Block (BPLE). Comparative Study.
Official title: Which Approach to Favor for Ultrasound-guided Lumbar Plexus Block (BPLE). Comparative Study.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Volunteers
Keywords: Lumbar plexus
ultrasound guided
Trident
Shamrock
Lead sponsor: Centre Hospitalier Universitaire de Saint Etienne
Sponsor class: OTHER
First posted: 2023-03-09
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult with indication of lumbar echography will be included.

Brief summary: Lumbar plexus block is described as a difficult block, thus requiring experienced practitioners. Many techniques have been used to date, notably anatomical landmarks, neurostimulation, and ultrasound-guided techniques. Among ultrasound-guided techniques, the "Trident" technique was described in 2006, while the "Shamrock" technique was described in 2013. Trident consists in putting the probe sagittally next to the lumbar spine and injecting local anesthetic around the lumbar plexus inside the psoas muscle at the level of L4. It is an out-of-plane puncture.

Shamrock puts the probe transversely on the iliac crest. Authors of the 2013 article said the image obtained with this technique was an image of L4. This technique allows an in-plane puncture, which is a safe technique.

Detailed description: This study aims at describing the level obtained with Shamrock, as well as at comparing depth of lumbar plexus, image quality and presence of vessels between the two techniques.

Eligibility criteria: Inclusion Criteria:

* Adult with indication of lumbar echography

Exclusion Criteria:

* Antecedent of spine surgery or spinal malformation

Primary outcomes:
measure: Projection of line C on the costiform processes
timeFrame: Day: 0
Secondary outcomes:
measure: Depth of lumbar plexus
timeFrame: Day: 0
measure: image quality
timeFrame: Day: 0
measure: presence of vessels
timeFrame: Day: 0
Other outcomes:
Locations:
city: Saint-Étienne
country: France
facility: CHU Saint-Etienne
Study officials:
affiliation: CHU SAINT-ETIENNE
name: Maxime WODEY, resident
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02167763: Comparative Study of the VeraCept Low-Dose Intrauterine Copper Contraceptive vs. the TCu380 Copper IUD
Official title: Study of the VeraCept Intrauterine Device for Long Acting Reversible Contraception
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Prevention of Pregnancy
Keywords: contraception
IUD
copper
Lead sponsor: Sebela Pharmaceuticals Inc.
Sponsor class: INDUSTRY
First posted: 2014-06-19
Enrollment: 300
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 42
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to evaluate the safety and effectiveness of the VeraCept Low Dose Intrauterine Copper Contraceptive compared to the standard T shaped copper IUD, the TCu380.

Detailed description: This is a prospective, randomized, subject-blinded, two arm controlled study of the Safety, Feasibility and Effectiveness of the VeraCept low-dose intrauterine copper contraceptive as compared to a concurrently controlled, commercially available standard copper "T" IUD (TCu380).

Eligibility criteria: Inclusion Criteria:

* Adult females ages 18 to 42 (pre-menopausal)
* Have had at least one child (parous) and currently seeking long acting reversible contraception
* Normal uterine cavity as determined by ultrasound
* Willing to sign informed consent
* Able and willing to comply with study assessment schedule

Exclusion Criteria:

* Post menopausal
* Pregnant (at time of enrollment)
* Known anatomical abnormalities of uterus, cervix and/or fallopian tubes
* Diagnosed or in treatment for cancer
* Untreated acute cervicitis
* In treatment for active Pelvic Inflammatory Disease
* Unexplained uterine bleeding or menometrorrhagia
* Known allergy to copper (Wilson's Disease) or imaging contrast media
* Unsuitable for study participation in the opinion of the Principal Investigator

Primary outcomes:
measure: Contraceptive Effectiveness
timeFrame: 12 Months
measure: Placement Feasibility
timeFrame: At Enrollment
Secondary outcomes:
measure: Device Expulsion
timeFrame: 12 Months
measure: Tolerability
timeFrame: 12 Months
measure: Pain at Insertion
timeFrame: At Enrollment
Other outcomes:
Locations:
city: La Romana
country: Dominican Republic
facility: Clinica Canela
Study officials:
affiliation: Clinica Canela
name: Juan M. Canela, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06581263: Psychedelic Virtual Reality
Official title: Investigating the Use of Virtual Reality in Psychedelic Research or Clinical Practice
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Psychedelic Experiences
Virtual Reality
Healthy Volunteer
Lead sponsor: Yale University
Sponsor class: OTHER
First posted: 2024-09-03
Enrollment: 15
Sex: ALL
Minimum age (years): 21
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CROSSOVER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy volunteers

Brief summary: The purpose of this study is to evaluate a novel VRP.

Detailed description: The primary objective of this study is to determine whether the subjective experience of a novel VRP (DeepDream) will be comparable to a standard dose of psychedelics. This study also looks to compare the subjective experience of DeepDream VRP to other available VR modalities developed to mimic psychedelic subjective experience along with assessing the incidence of VRP adverse effects.

Eligibility criteria: Inclusion Criteria:

* Ability to provide informed consent
* No history or current DSM-V diagnosis

Exclusion Criteria:

* Unstable medical conditions

Primary outcomes:
measure: Assess subjective experience of novel VRP (DeepDream) comparable to a standard dose of psychedelics.
timeFrame: Day 0 through Day 30
measure: Assess subjective experience of novel VRP (DeepDream) comparable to a standard dose of psychedelics.
timeFrame: Day 0 through Day 30
measure: Assess subjective experience of novel VRP (DeepDream) comparable to a standard dose of psychedelics.
timeFrame: Day 0 through Day 30
Secondary outcomes:
measure: Assess the incidence of VRP adverse effects, principally virtual reality sickness (VRS) and neck and upper back pain.
timeFrame: Day 0 through Day 30
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Yale University School of Medicine
state: Connecticut
Study officials:
affiliation: Yale University
name: Anahita Bassir Nia, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02501863: Analgesic Effect of Ropivacaine Plus Fentanyl vs Ropivacaine for Continuous 3-in-1 FNB After Total Knee Arthroplasty
Official title: Analgesic Effect of Ropivacaine Plus Fentanyl vs Ropivacaine for Continuous 3-in-1 FNB After Total Knee Arthroplasty
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pain
Lead sponsor: National Medical Center, Seoul
Sponsor class: OTHER
First posted: 2015-07-17
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The postoperative analgesic effect of the continuous 3-in-1 femoral nerve block (FNB) with ropivacaine/fentanyl or with ropivacaine were compared in total knee arthroplasty.

Detailed description: Forty patients of American Society of Anesthesiologist physical status Ⅰor Ⅱ undergoing total knee arthroplasty under spinal anesthesia would be enrolled and randomly divided into two groups (R, "3-in-1" using a 30 ml of ropivacaine 0.375% and a continuous 3-in-1 with a ropivacaine 0.2%(8mL/h) for 48 h after operation, RF: Fifty ug of fentanyl will be added to a bolus(30ml ropivacaine 0.375%) and 1ug/ml of fentanyl will be mixed to a continuous infusion(8mg/h, ropivacaine 0.2%). Spinal anesthesia will be done after the insertion of femoral catheter. IV PCA with hydromorphone(0.15mg/ml, 0-1-10), will be used for rescue analgesics. Visual analgesia scale, hydromorphone consumption, side effects until 48h after operation and satisfaction will be compared.

Eligibility criteria: Inclusion Criteria:

* ASA PS 1 to 3 undergoing total knee arthroplasty under spinal anesthesia

Exclusion Criteria:

* Patients were excluded from this study if they had contraindications to a regional anesthetic technique (e. g., local infection, sepsis, coagulation abnormality), allergy to local anesthetic or fentanyl, preexisting neurologic deficit in the lower extremities, and inability to comprehend the pain scales or use IV patient-controlled analgesia (PCA) device.

Primary outcomes:
measure: Pain on the VAS(Visual Analog Scale)
timeFrame: During 48 hour after operation
Secondary outcomes:
measure: Number of participant with side effects
timeFrame: During 48 hour after operation
Other outcomes:
Locations:
Study officials:
affiliation: National medical center
name: Mijung Yun, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01607463: The Effect of Transcutaneous Electrical Nerve Stimulation on Pain During Venous Cannulation
Official title: The Effect of Transcutaneous Electrical Nerve Stimulation on Pain During Venous Cannulation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cannulation Pain
Keywords: pain
transcutaneous electrical nerve stimulation
Lead sponsor: Kyungpook National University Hospital
Sponsor class: OTHER
First posted: 2012-05-30
Enrollment: 100
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: The purpose of this study was to investigate whether transcutaneous electrical nerve stimulation (TENS) could reduce pain during cannulation of vein.

Detailed description: One hundred patients were allocated randomly to two groups: In the active TENS group TENS was delivered via two electrodes on the venous cannulation site (radial side of the wrist of dominant forearm) 20 min prior to venous cannulation and control group received placebo (no current) TENS. Venous cannulation with a 22 gage cannula was performed. During venous cannulation the pain intensity (0 = no pain, 10 = worst pain imaginable) was measured. Any side effects during study periods were recorded

Eligibility criteria: Inclusion Criteria:

* outpatients who underwent plastic surgery

Exclusion Criteria:

* concomitant sedative or analgesic medication,
* neurological disease.
* all patients with potentially dangerous internal diseases (American Society of Anesthesiologists' physical status \> 3).

Primary outcomes:
measure: The effect of transcutaneous electrical nerve stimulation on pain during venous cannulation
timeFrame: one minute after cannulation
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: 2. Anesthesiology and Pain Medicine, Kyungpook National University Hospital
name: Younghoon Jeon, Dr
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kim S, Park K, Son B, Jeon Y. The effect of transcutaneous electrical nerve stimulation on pain during venous cannulation. Curr Ther Res Clin Exp. 2012 Sep;73(4-5):134-9. doi: 10.1016/j.curtheres.2012.05.001.
Clinical trial NCT01364363: Unrelated Donor Stem Cell Transplantation
Official title: Allogeneic Hematopoietic Progenitor Cell Transplantation From Unrelated Donors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Severe Aplastic Anemia
Paroxysmal Nocturnal Hemoglobinuria
Acute Myelogenous Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndromes
Myeloproliferative Syndromes
Chronic Myelogenous Leukemia
Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Multiple Myeloma
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Large Granulocytic Leukemia
Keywords: Transplant
Allogeneic
Allogeneic transplant
Unrelated donor transplant
MUD
HSCT
Stem cell transplant
Lead sponsor: Scripps Health
Sponsor class: OTHER
First posted: 2011-06-02
Enrollment: 64
Sex: ALL
Minimum age (years): 18
Maximum age (years): 69
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to provide an opportunity for patients with malignancies or bone marrow failure states who lack a suitable sibling donor to undergo allogeneic hematopoietic progenitor cell transplantation using cells from unrelated individuals or cord blood registries.

Detailed description: same

Eligibility criteria: Inclusion Criteria:

* \> 18 years of Age
* \< 70 years
* ECOG performance status 0, 1 or 2
* Left Ventricular Ejection Fraction \> 30%
* Creatinine clearance \> 40ml/min
* Transaminases \< 2X normal
* Total bilirubin \< 2X normal
* HIV seronegativity
* Weight \< 70kg for cord blood transplantation
* Ability to cover the cost of the transplant, necessary medications, and transportation/housing.
* Caregiver must be available while outpatient

Exclusion Criteria:

* Greater than one antigen mismatch at HLA-A, B, C or DR plus one allele mismatch at HLA-A, B, C or DR

Primary outcomes:
measure: Bone Marrow and Peripheral Blood Chimerism
timeFrame: 30 days post-transplant
measure: Bone Marrow and Peripheral Blood Chimerism
timeFrame: 100 days post-transplant
measure: Bone Marrow and Peripheral Blood Chimerism
timeFrame: 365 days post-transplant
Secondary outcomes:
Other outcomes:
Locations:
city: La Jolla
country: United States
facility: Scripps Green Hospital
state: California
Study officials:
affiliation: Scripps Clinic Medical Group
name: Jeffrey W. Andrey, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01665963: Efficacy of TopClosure(C)System in Healing Complicated Pacemaker Wounds
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Wounds and Injuries
Lead sponsor: Hillel Yaffe Medical Center
Sponsor class: OTHER_GOV
First posted: 2012-08-16
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patients receiving oral anticoagulation or anti-platelet therapy are at high risk of hematoma after device implantation. This study intends to examine the efficacy of the TopClosure(c) System in wound healing in these patients.


Eligibility criteria: Inclusion Criteria:

* Patients treated with anticoagulant therapy
* Patients treated with antiplatelet therapy

Exclusion Criteria:

* None

Primary outcomes:
measure: Efficacy of TopClosure(c) System
timeFrame: 10 days
Secondary outcomes:
Other outcomes:
Locations:
city: Hadera
country: Israel
facility: Hillel Yaffe Medical Center
Study officials:
References:
Clinical trial NCT03866863: Intra Uterine Growth Restriction
Official title: Intra Uterine Growth Restriction. Minimum Required Evidence-based Care and Neonatal Prognosis: Impact of Healthcare Pathways
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Intrauterine Growth Restriction
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2019-03-07
Enrollment: 31052
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All birth more than 24 + 0 weeks of amenorrhea at the maternity ward of the hospital Femme-Mère-Enfant from 1st of january 2011 to 31 december 2017.

Brief summary: Intrauterine growth restriction (IUGR) is associated with an increase in perinatal mortality and morbidity, as well as longer-term neurological, cognitive, cardiovascular and endocrine complications. In Europe, about 400,000 pregnancies per year are complicated by IUGR. However, antenatal diagnosis seems insufficient in clinical practice, making it impossible to recognize up to 75% of foetuses with IUGR. At a time when the use of good clinical practice has demonstrated a significant improvement in neonatal survival without severe morbidity, foetuses with IUGR are less likely to receive optimal care. Our hypothesis is that the rate of IUGR diagnosed underestimates the rate of actual IUGR.


Eligibility criteria: Inclusion Criteria:

* All birth more than 24 + 0 weeks of amenorrhea at the maternity ward of the hospital Femme-Mère-Enfant
* from 1st of january 2011 to 31 december 2017.

Exclusion Criteria:

* Infants born out of the hospital and secondarily hospitalized in the hospital Femme-Mère-Enfant .
* Multiple pregnancies,
* children with congenital fetal anomalies
* pregnancies without first trimester ultrasound (to date the pregnancy)

Primary outcomes:
measure: Number of patients diagnosed with Intrauterine growth restriction
timeFrame: Between 2011 and 2017
Secondary outcomes:
Other outcomes:
Locations:
city: Bron
country: France
facility: Hôpital Femme Mère Enfant
Study officials:
affiliation: Hospices Civils de Lyon
name: Muriel DORET, Prof.
role: PRINCIPAL_INVESTIGATOR
References: